Government Takes Bold Step: 16 Fixed-Dose Combination Drugs Banned for Public Safety

New Regulations on Fixed-Dose Combination Drugs

New Delhi: The Indian government has announced a ban on the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) medications, citing a lack of "therapeutic justification" and potential risks outweighing their benefits.

According to the Union Health Ministry, this decision aims to protect public health and ensure that only effective and scientifically validated medications are accessible to the public.

FDCs are defined as drugs that combine two or more active pharmaceutical ingredients (APIs) in a specific ratio.

This ban follows a comprehensive review of FDCs mandated by the Supreme Court. An expert committee formed by the Drugs Technical Advisory Board (DTAB) evaluated various drug combinations to identify those deemed irrational, therapeutically unjustified, or potentially harmful.

"The manufacture, sale, distribution, and supply of the identified 16 FDCs for human use will be prohibited immediately across the nation," stated the Ministry.

The Ministry further explained that these combination drugs were found to "lack therapeutic justification" and were deemed "not beneficial" considering the associated risks.

The prohibited formulations cover a variety of therapeutic categories, including certain dermatological products, analgesics (pain relievers), antispasmodics (muscle relaxants), and antibiotic combinations.

Some of the banned combinations include Acetyl Salicylic Acid with Ethoheptazine, Dicyclomine with Paracetamol and Clidinium Bromide, and Gliclazide with Chromium Picolinate.

Additionally, several antibiotic combinations such as Amoxicillin with Serratiopeptidase and Cefuroxime with Serratiopeptidase have also been included in the ban.

The list also features various dermatological and skincare products that combine Aloe Vera or Aloe Extract with ingredients like Vitamin E and Tea Tree Oil.

This ban was enacted under Section 26A of the Drugs and Cosmetics Act, 1940.

The Ministry emphasized that this action is part of the government's ongoing efforts to promote rational medication use and enhance patient safety, recalling that several irrational FDCs have been banned in previous years following thorough scientific evaluations.

All state drug controllers, regulatory bodies, and enforcement agencies have been instructed to ensure strict adherence to these notifications.

Manufacturers, importers, distributors, and other stakeholders are encouraged to implement necessary corrective actions to comply with the new regulations.